Literature DB >> 22806060

Comment on Rosenbaum-Krumme et al.: (18)F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Francesco Bertagna, Raffaele Giubbini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806060     DOI: 10.1007/s00259-012-2191-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

Review 1.  Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review.

Authors:  Kerstin Kathrine Soelberg; Steen Joop Bonnema; Thomas Heiberg Brix; Laszlo Hegedüs
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

2.  ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Authors:  Sandra J Rosenbaum-Krumme; Rainer Görges; Andreas Bockisch; Ina Binse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-21       Impact factor: 9.236

3.  Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.

Authors:  Florian Grabellus; James Nagarajah; Andreas Bockisch; Kurt Werner Schmid; Sien-Yi Sheu
Journal:  Clin Nucl Med       Date:  2012-02       Impact factor: 7.794

4.  Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas associates with GLUT1 plasmamembrane expression.

Authors:  F Morani; L Pagano; F Prodam; G Aimaretti; C Isidoro
Journal:  Panminerva Med       Date:  2012-06       Impact factor: 5.197

5.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.

Authors:  U Feine; R Lietzenmayer; J P Hanke; J Held; H Wöhrle; W Müller-Schauenburg
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.